title: Influence of lys656asn polymorphism of leptin receptor gene on surgical results of biliopancreatic diversion.
abstract: BACKGROUND
  Bariatric surgery is the most effective long-term treatment for morbid obesity, reducing obesity-associated comorbidities. The purpose of the present study was to evaluate Lys656Asn polymorphism of leptin receptor gene on outcomes 1 year after biliopancreatic diversion.
  
  
  METHODS
  A sample of 41 morbidly obese patients (body mass index (BMI) > 40 kg/m(2)) were operated on. Biochemical and anthropometric evaluation were realized at basal visit and at each visit. The frequency of patients with diabetes mellitus, hypertension, and hyperlipidemia was recorded at each visit.
  
  
  RESULTS
  Thirty-two patients (78%) had genotype Lys656/Lys656, eight patients (19.5%) Lys656/Asn656 genotype, and one patient (2.4%) Asn656/Asn656 genotype. In the wild-type group, body mass index, weight, glucose, total cholesterol, LDL cholesterol, triacylglycerol, and systolic blood pressure decreased. In the mutant group, the same parameters improved. Initial weight percent loss at 1 year of follow-up was higher in mutant group than in wild-type group (38.9% vs 29.9%; p < 0.05). Total weight loss was higher in mutant group than wild-type group (50.7 vs 37.2 kg; p < 0.05). Basal weight and BMI were higher in mutant group than wild type.
  
  
  CONCLUSIONS
  Weight loss was higher in mutant group (Lys656Asn and Asn656Asn) than wild-type group (Lys656Lys) after bariatric surgery. Carriers of the allelic variant (Asn) had higher basal weight.
authors.affiliation: Unit of Investigation and Endocrinology Department, Hospital Rio Hortega, Institute of Endocrinology and Nutrition, Medicine School, University of Valladolid, Valladolid 47130, Spain. dadluis@yahoo.es
authors.forename: Daniel Antonio
authors.initials: DA
authors.lastname: de Luis
authors.forename: Rocio
authors.initials: R
authors.lastname: Aller
authors.forename: Manuel González
authors.initials: MG
authors.lastname: Sagrado
authors.forename: Olatz
authors.initials: O
authors.lastname: Izaola
authors.forename: Maria Concepcion
authors.initials: MC
authors.lastname: Terroba
authors.forename: Luis
authors.initials: L
authors.lastname: Cuellar
authors.forename: Rosa
authors.initials: R
authors.lastname: Conde
authors.forename: Tomas
authors.initials: T
authors.lastname: Martin
mesh_terms: D000328:Adult; D017677:Age Distribution; D015904:Biliopancreatic Diversion / Q000009:adverse effects / Q000379:methods*; D001786:Blood Glucose / Q000032:analysis; D001795:Blood Pressure Determination; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery*; D011110:Polymorphism, Genetic; D011183:Postoperative Complications / Q000175:diagnosis* / Q000453:epidemiology; D011336:Probability; D054411:Receptors, Leptin / Q000235:genetics* / Q000378:metabolism; D018570:Risk Assessment; D017678:Sex Distribution; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome; D015431:Weight Loss / Q000235:genetics
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D054411:Receptors, Leptin